🇺🇸 insulin degludec/insulin aspart in United States
4 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 28 March 2025 – 28 March 2026
- Total reports: 4
Most-reported reactions
- Cardiac Arrest — 1 report (25%)
- Chronic Kidney Disease — 1 report (25%)
- Diarrhoea — 1 report (25%)
- Mineral Metabolism Disorder — 1 report (25%)
Frequently asked questions
Is insulin degludec/insulin aspart approved in United States?
insulin degludec/insulin aspart does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for insulin degludec/insulin aspart in United States?
Novo Nordisk A/S is the originator. The local marketing authorisation holder may differ — check the official source linked above.